Cargando…
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition
Cells that are deficient in homologous recombination, such as those that have mutations in any of the Fanconi Anemia (FA)/BRCA genes, are hypersensitive to inhibition of poly(ADP-ribose) polymerase (PARP). However, FA/BRCA-deficient tumors represent a small fraction of breast cancers, which might re...
Autores principales: | Cruz, Olga Villamar, Prudnikova, Tatiana Y., Araiza-Olivera, Daniela, Perez-Plasencia, Carlos, Johnson, Neil, Bernhardy, Andrea J., Slifker, Michael, Renner, Catherine, Chernoff, Jonathan, Arias, Luis E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363532/ https://www.ncbi.nlm.nih.gov/pubmed/27740936 http://dx.doi.org/10.18632/oncotarget.12576 |
Ejemplares similares
-
Suppression of RAC1-driven malignant melanoma by Group A PAK inhibitors
por: Araiza-Olivera, Daniela, et al.
Publicado: (2017) -
COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011) -
Effects of p21-activated kinase 1 inhibition on 11q13 amplified ovarian cancer cells
por: Prudnikova, Tatiana Y., et al.
Publicado: (2015) -
Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022) -
A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells
por: Arias-Romero, Luis E., et al.
Publicado: (2010)